Progyny, Inc. Reports Record Q2 2025 Revenue

Progyny, Inc. ( (PGNY) ) has released its Q2 earnings. Here is a breakdown of the information Progyny, Inc. presented to its investors.

Progyny, Inc. is a global leader in women’s health and family building solutions, providing comprehensive benefits that empower patients with support, education, and access to a network of specialists. The company operates in the healthcare sector, focusing on fertility and family building services.

Progyny, Inc. reported a record revenue of $332.9 million for the second quarter of 2025, marking a 9.5% growth compared to the previous year. The company also generated $55.5 million in quarterly operating cash flow and raised its full-year guidance, reflecting increased member engagement.

Key financial highlights include an 11% increase in fertility benefit services revenue and an 8% rise in pharmacy benefit services revenue. The company’s gross profit grew by 16% to $79 million, with a gross margin expansion to 23.7%. Net income stood at $17.1 million, or $0.19 per diluted share, while Adjusted EBITDA increased by 6.4% to $57.9 million. Despite a large client not renewing its services, revenue excluding this client increased by 18%.

Progyny’s financial position remains strong with $305.1 million in cash and marketable securities and no debt. The company has also secured a $200 million revolving credit facility to enhance its financial flexibility. As of June 30, 2025, Progyny had 542 fertility and family building clients, up from 463 the previous year.

Looking ahead, Progyny’s management remains optimistic about continued growth, with revenue for the full year 2025 projected to be between $1.235 billion and $1.270 billion. The company anticipates strong member engagement and plans to leverage its strategic investments to enhance member experience and integrate recent acquisitions.